Identification
NameHydrocodone
Accession NumberDB00956  (APRD00591, DB09475)
TypeSmall Molecule
GroupsApproved, Illicit
Description

Narcotic analgesic related to codeine, but more potent and more addicting by weight. It is used also as cough suppressant.

Structure
Thumb
Synonyms
(-)-Dihydrocodeinone
4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one
Dihydrocodeinone
Hidrocodona
Hydrocodon
Hydrocodone polistirex
Hydrocodonum
Hydrocone
Hydroconum
Idrocodone
External IDs NSC-19044
Product Ingredients
IngredientUNIICASInChI KeyDetails
Hydrocodone bitartrateNO70W886KK 34195-34-1JMBRWJAVUIITGV-LNNMZZBZSA-NDetails
Hydrocodone hydrochlorideQKZ0920OV3 25968-91-6GCJAEXSZUXBMFS-RNWHKREASA-NDetails
Hydrocodone polistirexNot AvailableNot AvailableNot applicableDetails
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hycodan SyrupSyrup1 mgOralBristol Myers Squibb1992-12-31Not applicableCanada
Hycodan TabletsTablet5 mgOralBristol Myers Squibb1992-12-31Not applicableCanada
Hysingla ERTablet, extended release60 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release120 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release30 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release80 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release40 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release100 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release20 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Pdp-hydrocodoneSyrup1 mgOralPendopharm Division Of De Pharmascience Inc2009-03-21Not applicableCanada
Robidone 1mg/ml SyrSyrup1 mgOralWyeth Ayerst Canada Inc.1993-12-312001-11-06Canada
Robidone Syr 1mg/mlSyrup1 mgOralAyerst Laboratories1991-12-311997-08-15Canada
ZohydroCapsule, extended release10 mg/1OralZogenix, Inc.2013-10-25Not applicableUs
ZohydroCapsule, extended release20 mg/1OralZogenix, Inc.2013-10-25Not applicableUs
ZohydroCapsule, extended release50 mg/1OralZogenix, Inc.2013-10-25Not applicableUs
ZohydroCapsule, extended release30 mg/1OralZogenix, Inc.2013-10-25Not applicableUs
ZohydroCapsule, extended release10 mg/1OralZogenix, Inc.2013-10-25Not applicableUs
ZohydroCapsule, extended release15 mg/1OralZogenix, Inc.2013-10-25Not applicableUs
ZohydroCapsule, extended release30 mg/1OralZogenix, Inc.2013-10-25Not applicableUs
ZohydroCapsule, extended release40 mg/1OralZogenix, Inc.2013-10-25Not applicableUs
ZohydroCapsule, extended release15 mg/1OralZogenix, Inc.2013-10-25Not applicableUs
ZohydroCapsule, extended release40 mg/1OralZogenix, Inc.2013-10-25Not applicableUs
ZohydroCapsule, extended release20 mg/1OralZogenix, Inc.2013-10-25Not applicableUs
ZohydroCapsule, extended release50 mg/1OralZogenix, Inc.2013-10-25Not applicableUs
Zohydro ERCapsule, extended release10 mg/1OralPernix Therapeutics2013-10-25Not applicableUs
Zohydro ERCapsule, extended release30 mg/1OralPernix Therapeutics2013-10-25Not applicableUs
Zohydro ERCapsule, extended release15 mg/1OralPernix Therapeutics2013-10-25Not applicableUs
Zohydro ERCapsule, extended release40 mg/1OralPernix Therapeutics2013-10-25Not applicableUs
Zohydro ERCapsule, extended release20 mg/1OralPernix Therapeutics2013-10-25Not applicableUs
Zohydro ERCapsule, extended release50 mg/1OralPernix Therapeutics2013-10-25Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Caldomine Dh AdulteLiquidOralTechnilab Pharma Inc.1981-12-312001-04-04Canada
Caldomine Dh EnfantLiquidOralTechnilab Pharma Inc.1982-12-312001-04-04Canada
CodofenTabletOralPaladin Labs IncNot applicableNot applicableCanada
Coristine-DH LiqSyrupOralTechnilab Pharma Inc.1988-12-312006-07-28Canada
DalmacolLiquidOralLaboratoire Riva Inc1997-03-26Not applicableCanada
Dimetane Expectorant DcSyrupOralPfizer Laboratories Div Pfizer Inc.2001-09-06Not applicableCanada
Dimetane Expectorant-DC SyrSyrupOralWhitehall Robins Inc.1993-12-312001-04-10Canada
FlowtussLiquidOralMission Pharmacal2015-08-18Not applicableUs
HycetSolutionOralGw Pharmaceuticals Ltd.2011-02-01Not applicableUs
HycofenixLiquidOralMission Pharmacal2015-08-18Not applicableUs
HycomineSyrupOralBristol Myers Squibb1993-12-312011-05-24Canada
Hycomine-SSyrupOralBristol Myers Squibb1994-12-312009-10-05Canada
Hydrocodone AcetaminophenTabletOralRed Pharm Drug, Inc.2011-03-03Not applicableUs
Hydrocodone Bit/apapTabletOralMesource Pharmaceuticals2011-07-01Not applicableUs
Hydrocodone Bitartate and AcetaminophenTabletOralActavis Pharma Company1997-06-25Not applicableUs00591 3202 01 nlmimage10 c11fe0ff
Hydrocodone BitartrateTabletOralDirectrx2014-01-01Not applicableUs53746 0110 05 nlmimage10 e315f1bf
Hydrocodone Bitartrate and AcetaminophenSolutionOralPharmaceutical Associates, Inc.2011-01-012016-03-11Us
Hydrocodone Bitartrate and Acetaminophen TabletsTabletOralRed Pharm Drug, Inc.2010-02-18Not applicableUs
Hydrocodone Bitartrate and Chlorpheniramine MaleateSolutionOralAcella Pharmaceuticals, LLC2017-06-14Not applicableUs
Hydrocodone Bitartrate and Chlorpheniramine Maleate SolutionSolutionOralTris Pharma, Inc.2015-03-012016-11-30Us
Hydrocodone Bitartrate and Homatropine MethylbromideSyrupOralPharmaceutical Associates, Inc.2009-12-28Not applicableUs
Hydrocodone Bitartrate and IbuprofenTablet, film coatedOralTeva2003-04-152016-01-31Us00093 5161 01 nlmimage10 6342b1c5
Hydrocodone Bitartrate and Pseudoephedrine Hydrochloride SolutionSolutionOralTris Pharma, Inc.2014-12-312016-11-18Us
Hydrocodone Bitartrate Chlorpheniramine Maleate and Pseudoephedrine HydrochlorideSolutionOralBio Pharm, Inc.2017-05-16Not applicableUs
Hydrocodone Bitartrate, Chlorpheniramine Maleate and Pseudoephedrine HydrochlorideSolutionOralPaddock Laboratories, Inc.2014-08-26Not applicableUs
Hydrocodone Bitartrate, Chlorpheniramine Maleate, and Pseudoephedrine HClSolutionOralCypress Pharmaceuticals, Inc.2014-01-09Not applicableUs
Hydrocodone Bitartrate, Chlorpheniramine Maleate, and Pseudoephedrine Hydrochloride Oral SolutionSolutionOralTris Pharma, Inc.2015-01-042016-11-30Us
Hydrocodone Bitatrate and AcetaminophenTabletOralLake Erie Medical Dba Quality Care Produts Llc2014-10-06Not applicableUs
Hydrocodone Polistirex and Chlorpheniramine PolisitrexSuspension, extended releaseOralAtlantic Biologicals Corps.2012-08-16Not applicableUs
Hydrocodone Polistirex and Chlorpheniramine PolistirexSuspension, extended releaseOralNeos Therapeutics, Lp2014-10-23Not applicableUs
Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-releaseSuspension, extended releaseOralAristos Phamaceuticals, Inc.2012-06-292016-10-13Us
Hydrocodone Polistirex and Chlorpheniramine Polistirex PennkineticSuspension, extended releaseOralKremers Urban1987-12-31Not applicableUs
Hydrocodone/apapTabletOralPharm Pak, Inc.2014-09-01Not applicableUs
HydrometSolutionOralActavis Pharma Company2002-09-30Not applicableUs
Hyrdrocodone ApapTabletOralDirectrx2015-01-01Not applicableUs
IbucodoneTabletOralPaladin Labs IncNot applicableNot applicableCanada
IbudoneTablet, film coatedOralPoly Pharmaceuticals2006-11-06Not applicableUs
LorcetTabletOralCardinal Health1992-05-292016-10-13Us
Lorcet 10/650TabletOralRx Pak Division Of Mc Kesson Corporation2001-12-212017-04-25Us
Lorcet HdTabletOralMayne Pharma2014-04-01Not applicableUs
Lorcet PlusTabletOralCardinal Health1988-06-292016-10-13Us
LortabSyrupOralECR Pharmaceuticals Co., Inc.2013-09-252016-10-13Us
Lortab 10/325TabletOralUcb Inc2014-04-212017-07-14Us
Lortab 5/325TabletOralUcb Inc2014-04-212017-07-14Us
Lortab 7.5/325TabletOralUcb Inc2014-04-212017-07-14Us
MaxidoneTabletOralWatson Pharma, Inc.2013-03-12Not applicableUs
Mercodol With DecaprynSyrupOralAventis Pharma Ltd.1994-12-312001-07-20Canada
NorcoTabletOralPhysicians Total Care, Inc.1998-05-13Not applicableUs
Novahistex DhSyrupOralSanofi Aventis1994-12-31Not applicableCanada
Novahistex Dh ExpectorantSyrupOralAventis Pharma Ltd.1994-12-312003-07-22Canada
Novahistine DhSyrupOralSanofi Aventis1994-12-31Not applicableCanada
ObredonSolutionOralNovotec Pharma Llc2014-12-30Not applicableUs
Ratio-calmydoneSyrupOralTeva1981-12-312017-04-04Canada
Ratio-coristex-DHSyrupOralRatiopharm Inc Division Of Teva Canada Limited1986-12-312015-08-21Canada
ReprexainTabletOralStat Rx USA2008-12-16Not applicableUs
ReziraSolutionOralHawthorn Pharmaceuticals, Inc.2011-06-08Not applicableUs
Theracodophen-325KitPhysician Therapeutics Llc2011-02-082016-10-13Us
Theracodophen-650KitPhysician Therapeutics Llc2011-03-062016-10-13Us
Theracodophen-750KitPhysician Therapeutics Llc2011-02-092016-10-13Us
Theracodophen-low-90KitPhysician Therapeutics Llc2011-02-022016-10-13Us
Triaminic Expectorant Dh SyrupSyrupOralNovartis1993-12-312001-04-06Canada
Tussaminic Dh Forte SyrupSyrupOralNovartis1992-12-312001-04-06Canada
Tussaminic Dh Pediatric SyrupSyrupOralNovartis1993-12-312001-04-06Canada
TussicapsCapsule, extended releaseOralECR Pharmaceuticals Co., Inc.2011-09-02Not applicableUs
TussigonTabletOralPfizer Laboratories Div Pfizer Inc.1985-07-30Not applicableUs61570 0081 01 nlmimage10 4d1da69d
TussionexSuspensionOralSanofi Aventis1957-12-31Not applicableCanada
Tussionex PennkineticSuspension, extended releaseOralUnither Pharmaceuticals1987-12-31Not applicableUs
Vasofrinic DhSyrupOralLaboratoires Trianon Inc1979-12-312017-03-10Canada
VicodinTabletOralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc1983-01-07Not applicableUs
Vicodin EsTabletOralCardinal Health2010-05-182016-10-13Us00074 1973 54 nlmimage10 be1ddf0e
Vicodin HpTabletOralCardinal Health1996-09-232016-10-13Us
VicoprofenTablet, film coatedOralAbbvie1997-09-232016-10-13Us
VituzSolutionOralHawthorn Pharmaceuticals, Inc.2013-04-01Not applicableUs
XodolTabletOralRebel Distributors2004-06-23Not applicableUs
Xylon 10TabletOralSircle Laboratories, Llc2014-07-01Not applicableUs
ZamicetSolutionOralPharmaceutical Associates, Inc.2015-03-18Not applicableUs
ZutriproSolutionOralHawthorn Pharmaceuticals, Inc.2011-06-08Not applicableUs
ZydoneTabletOralStat Rx USA1998-12-01Not applicableUs
ZyfrelSolutionOralHawthorn Pharmaceuticals, Inc.2016-04-14Not applicableUs
Categories
UNII6YKS4Y3WQ7
CAS number125-29-1
WeightAverage: 299.3642
Monoisotopic: 299.152143543
Chemical FormulaC18H21NO3
InChI KeyLLPOLZWFYMWNKH-CMKMFDCUSA-N
InChI
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
IUPAC Name
(1S,5R,13R,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
Pharmacology
Indication

For relief of moderate to moderately severe pain. Also used for the symptomatic relief of nonproductive cough, alone or in combination with other antitussives or expectorants.

Structured Indications
Pharmacodynamics

Hydrocodone, a semisynthetic opiate agonist and hydrogenated ketone derivative, is similar to other phenanthrene derivatives, such as codeine. Used as an analgesic, hydrocodone is combined with acetaminophen, ibuprofen, or aspirin to treat pain. Used as an antitussive, hydrocodone is combined with phenylephrine, pseudoephedrine, phenylpropanolamine, guaifenesin, pyrilamine, pheniramine, or chlorpheniramine. Opiate agonists exert their principal pharmacologic effect at specific receptor binding sites in the CNS and other tissues. There are several subtypes of opiate receptors including the mu receptor (localized in pain modulating regions of the CNS), the kappa receptor (localized in the deep layers of the cerebral cortex), the delta receptor (localized in the limbic regions of the CNS), and the sigma receptor (thought to mediate the dysphoric and psychotomimetic effects of some opiate partial agonists). Agonist activity at the mu or kappa receptor can result in analgesia, miosis, and/or decreased body temperature. Agonist activity at the mu receptor can also result in suppression of opiate withdrawal, whereas antagonist activity can result in precipitation of withdrawal. Opiate agonists act at several sites within the CNS involving several systems of neurotransmitters to produce analgesia, but the precise mechanism of action has not been fully determined. Opiate agonists do not alter the threshold or responsiveness of afferent nerve endings to noxious stimuli nor the conduction of impulses along peripheral nerves. Instead, they alter the perception of pain at the spinal cord and higher levels in the CNS and the person's emotional response to pain.

Mechanism of action

Hydrocodone acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Hydrocodone primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as hydrocodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Delta-type opioid receptorProteinyes
agonist
HumanP41143 details
Related Articles
Absorption

Well absorbed from the gastrointestinal tract.

Volume of distributionNot Available
Protein binding

As most agents in the 5-ring morphinan group of semi-synthetic opioids bind plasma protein to a similar degree (range 19% [hydromorphone] to 45% [oxycodone]), hydrocodone is expected to fall within this range.

Metabolism

Hepatic and also in intestinal mucosa.

SubstrateEnzymesProduct
Hydrocodone
hydromorphoneDetails
Hydrocodone
norhydrocodoneDetails
Route of eliminationNot Available
Half life

1.25-3 hours

ClearanceNot Available
Toxicity

Symptoms of overdose include respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, dizziness, ringing in the ears, confusion, blurred vision, eye problems, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdose, apnea, circulatory collapse, cardiac arrest and death may occur. LD50=85.7mg/kg (subcutaneous, in mice).

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Hydrocodone.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Hydrocodone.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Hydrocodone.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Hydrocodone.Experimental, Illicit
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Hydrocodone.Experimental
AbirateroneThe serum concentration of Hydrocodone can be increased when it is combined with Abiraterone.Approved
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Hydrocodone.Approved
Adipiplonadipiplon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Hydrocodone.Approved, Vet Approved
AllopregnanoloneSage 547 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Amiloride.Approved
AmiodaroneThe serum concentration of Hydrocodone can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AmlodipineThe serum concentration of Hydrocodone can be increased when it is combined with Amlodipine.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Hydrocodone which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Hydrocodone.Approved
AprepitantThe serum concentration of Hydrocodone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ArmodafinilThe serum concentration of Hydrocodone can be decreased when it is combined with Armodafinil.Approved, Investigational
ArtemetherThe serum concentration of Hydrocodone can be decreased when it is combined with Artemether.Approved
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AtazanavirThe serum concentration of Hydrocodone can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Hydrocodone can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Hydrocodone can be increased when it is combined with Atorvastatin.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hydrocodone.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Hydrocodone.Approved, Vet Approved
AzelastineHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Azosemide.Investigational
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Hydrocodone.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Hydrocodone.Withdrawn
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Hydrocodone.Approved
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BetaxololThe metabolism of Hydrocodone can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Hydrocodone can be decreased when it is combined with Bexarotene.Approved, Investigational
BicalutamideThe serum concentration of Hydrocodone can be increased when it is combined with Bicalutamide.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Hydrocodone.Approved
BL-1020BL-1020 may increase the hypotensive activities of Hydrocodone.Investigational
BoceprevirThe serum concentration of Hydrocodone can be increased when it is combined with Boceprevir.Withdrawn
BortezomibThe serum concentration of Hydrocodone can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Hydrocodone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bumetanide.Approved
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
BuprenorphineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Bupropion resulting in a loss in efficacy.Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Vet Approved
CalcitriolThe serum concentration of Hydrocodone can be decreased when it is combined with Calcitriol.Approved, Nutraceutical
Canrenoic acidThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Canrenone.Investigational
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit, Vet Approved
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Hydrocodone.Withdrawn
CelecoxibThe metabolism of Hydrocodone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Hydrocodone can be increased when it is combined with Ceritinib.Approved
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ChloroquineThe metabolism of Hydrocodone can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Hydrocodone.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Hydrocodone.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorthalidone.Approved
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CholecalciferolThe metabolism of Hydrocodone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cicletanine.Investigational
CilostazolThe serum concentration of Hydrocodone can be increased when it is combined with Cilostazol.Approved
CimetidineThe serum concentration of Hydrocodone can be increased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Cinacalcet resulting in a loss in efficacy.Approved
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
CiprofloxacinThe serum concentration of Hydrocodone can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe metabolism of Hydrocodone can be decreased when combined with Citalopram.Approved
ClarithromycinThe serum concentration of Hydrocodone can be increased when it is combined with Clarithromycin.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ClotrimazoleThe serum concentration of Hydrocodone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CobicistatThe serum concentration of Hydrocodone can be increased when it is combined with Cobicistat.Approved
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ConivaptanThe serum concentration of Hydrocodone can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Hydrocodone can be increased when it is combined with Crizotinib.Approved
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hydrocodone.Approved
CyclosporineThe serum concentration of Hydrocodone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cyclothiazide.Approved
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DabrafenibThe serum concentration of Hydrocodone can be decreased when it is combined with Dabrafenib.Approved
DalfopristinThe serum concentration of Hydrocodone can be increased when it is combined with Dalfopristin.Approved
DanazolThe serum concentration of Hydrocodone can be increased when it is combined with Danazol.Approved
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DapoxetineHydrocodone may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe metabolism of Hydrocodone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Hydrocodone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Hydrocodone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Hydrocodone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Hydrocodone can be increased when it is combined with Delavirdine.Approved
Deramciclanederamciclane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Desmopressin.Approved
DesvenlafaxineThe serum concentration of Hydrocodone can be decreased when it is combined with Desvenlafaxine.Approved
DexamethasoneThe serum concentration of Hydrocodone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Hydrocodone.Withdrawn
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Vet Approved
DicloxacillinThe serum concentration of Hydrocodone can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydrocodone.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Hydrocodone.Approved, Illicit
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
DihydroergotamineThe serum concentration of Hydrocodone can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
DiltiazemThe serum concentration of Hydrocodone can be increased when it is combined with Diltiazem.Approved
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DoxycyclineThe serum concentration of Hydrocodone can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
DronedaroneThe serum concentration of Hydrocodone can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
DrospirenoneThe serum concentration of Hydrocodone can be decreased when it is combined with Drospirenone.Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
DuloxetineThe metabolism of Hydrocodone can be decreased when combined with Duloxetine.Approved
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Efonidipine.Approved
EliglustatThe metabolism of Hydrocodone can be decreased when combined with Eliglustat.Approved
EltanolonePregnanolone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
EluxadolineHydrocodone may increase the constipating activities of Eluxadoline.Approved
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
EnzalutamideThe serum concentration of Hydrocodone can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Eplerenone.Approved
ErythromycinThe serum concentration of Hydrocodone can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramHydrocodone may increase the serotonergic activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Hydrocodone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
EstradiolThe serum concentration of Hydrocodone can be decreased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Etacrynic acid.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Hydrocodone.Approved
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EtoperidoneHydrocodone may increase the serotonergic activities of Etoperidone.Approved
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit, Vet Approved
EtravirineThe serum concentration of Hydrocodone can be decreased when it is combined with Etravirine.Approved
ExemestaneThe serum concentration of Hydrocodone can be decreased when it is combined with Exemestane.Approved, Investigational
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Withdrawn
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydrocodone.Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FluconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Fluconazole.Approved
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
FluoxetineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Fluoxetine resulting in a loss in efficacy.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Fluticasone propionateFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
FosamprenavirThe serum concentration of Hydrocodone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Hydrocodone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Hydrocodone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Hydrocodone can be increased when it is combined with Fusidic Acid.Approved
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Gabapentin Enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Hydrocodone.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
Glycerol PhenylbutyrateThe serum concentration of Hydrocodone can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Hydrocodone.Approved, Investigational, Vet Approved
GriseofulvinThe serum concentration of Hydrocodone can be decreased when it is combined with Griseofulvin.Approved, Vet Approved
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Hydrocodone.Experimental
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Hydrocodone.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocodone can be decreased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydroflumethiazide.Approved
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine hydrobromide may increase the analgesic activities of Hydrocodone.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hydrocodone.Approved
IdelalisibThe serum concentration of Hydrocodone can be increased when it is combined with Idelalisib.Approved
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ImatinibThe serum concentration of Hydrocodone can be increased when it is combined with Imatinib.Approved
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
IndalpineHydrocodone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Indapamide.Approved
IndinavirThe serum concentration of Hydrocodone can be increased when it is combined with Indinavir.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydrocodone.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Hydrocodone.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Hydrocodone.Withdrawn
IsavuconazoniumThe serum concentration of Hydrocodone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Hydrocodone.Approved
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
IsoniazidThe serum concentration of Hydrocodone can be increased when it is combined with Isoniazid.Approved
IsradipineThe serum concentration of Hydrocodone can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Hydrocodone can be increased when it is combined with Ivacaftor.Approved
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
KetoconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LapatinibThe serum concentration of Hydrocodone can be increased when it is combined with Lapatinib.Approved, Investigational
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LevomilnacipranHydrocodone may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Hydrocodone.Approved, Investigational
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit
LomitapideThe serum concentration of Hydrocodone can be increased when it is combined with Lomitapide.Approved
LopinavirThe serum concentration of Hydrocodone can be decreased when it is combined with Lopinavir.Approved
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LorcaserinThe metabolism of Hydrocodone can be decreased when combined with Lorcaserin.Approved
LovastatinThe serum concentration of Hydrocodone can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LuliconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Hydrocodone can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Hydrocodone can be decreased when it is combined with Lumefantrine.Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mannitol.Approved, Investigational
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Hydrocodone.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydrocodone.Approved
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Medroxyprogesterone acetateThe serum concentration of Hydrocodone can be decreased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MephedroneMephedrone may increase the analgesic activities of Hydrocodone.Investigational
MephentermineMephentermine may increase the analgesic activities of Hydrocodone.Approved
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mersalyl.Approved
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Hydrocodone.Approved
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methazolamide.Approved
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MethotrimeprazineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methyclothiazide.Approved
MethylecgonineECGONINE METHYL ESTER may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Hydrocodone.Investigational
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Hydrocodone.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Metolazone.Approved
MetoprololThe metabolism of Hydrocodone can be decreased when combined with Metoprolol.Approved, Investigational
MetyraponeThe serum concentration of Hydrocodone can be decreased when it is combined with Metyrapone.Approved
MetyrosineHydrocodone may increase the sedative activities of Metyrosine.Approved
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
MifepristoneThe serum concentration of Hydrocodone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranHydrocodone may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Hydrocodone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MirabegronThe metabolism of Hydrocodone can be decreased when combined with Mirabegron.Approved
MirtazapineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MitotaneThe serum concentration of Hydrocodone can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Hydrocodone.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Hydrocodone.Approved
ModafinilThe serum concentration of Hydrocodone can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MoricizineMoricizine may increase the hypotensive activities of Hydrocodone.Approved, Withdrawn
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
NafcillinThe serum concentration of Hydrocodone can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
NaltrexoneThe therapeutic efficacy of Hydrocodone can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe serum concentration of Hydrocodone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Hydrocodone can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Hydrocodone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Hydrocodone can be increased when it is combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Hydrocodone.Withdrawn
NicardipineThe serum concentration of Hydrocodone can be increased when it is combined with Nicardipine.Approved
NilotinibThe serum concentration of Hydrocodone can be increased when it is combined with Nilotinib.Approved, Investigational
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
Norflurane1,1,1,2 Tetrafluoroethane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
NorgestimateThe serum concentration of Hydrocodone can be decreased when it is combined with Norgestimate.Approved
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Hydrocodone.Withdrawn
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
OlaparibThe serum concentration of Hydrocodone can be increased when it is combined with Olaparib.Approved
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
OritavancinThe serum concentration of Hydrocodone can be decreased when it is combined with Oritavancin.Approved, Investigational
OrphenadrineHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
OsimertinibThe serum concentration of Hydrocodone can be increased when it is combined with Osimertinib.Approved
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OxcarbazepineThe serum concentration of Hydrocodone can be decreased when it is combined with Oxcarbazepine.Approved
OxethazaineOxetacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydrocodone.Approved, Investigational
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Hydrocodone.Approved
PaclitaxelThe serum concentration of Hydrocodone can be decreased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Hydrocodone can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Hydrocodone.Approved
PanobinostatThe serum concentration of Hydrocodone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Hydrocodone.Approved
ParoxetineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Paroxetine resulting in a loss in efficacy.Approved, Investigational
PazopanibThe serum concentration of Hydrocodone can be increased when it is combined with Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Hydrocodone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocodone.Approved
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Hydrocodone.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Hydrocodone.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Hydrocodone.Withdrawn
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Hydrocodone.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Hydrocodone.Approved, Illicit
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PioglitazoneThe serum concentration of Hydrocodone can be decreased when it is combined with Pioglitazone.Approved, Investigational
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydrocodone.Approved
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydrocodone.Approved
PiretanideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Piretanide.Experimental
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Hydrocodone.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Hydrocodone.Withdrawn
PolythiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Polythiazide.Approved
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PosaconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleHydrocodone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
PrednisoneThe serum concentration of Hydrocodone can be decreased when it is combined with Prednisone.Approved, Vet Approved
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hydrocodone.Approved
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Hydrocodone.Approved
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Hydrocodone.Investigational
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PseudoephedrinePseudoephedrine may increase the analgesic activities of Hydrocodone.Approved
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Quinethazone.Approved
QuinidineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Quinidine resulting in a loss in efficacy.Approved
QuinineThe metabolism of Hydrocodone can be decreased when combined with Quinine.Approved
QuinupristinThe serum concentration of Hydrocodone can be increased when it is combined with Quinupristin.Approved
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
RamosetronHydrocodone may increase the constipating activities of Ramosetron.Approved
RanolazineThe serum concentration of Hydrocodone can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Hydrocodone.Approved
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
RifabutinThe serum concentration of Hydrocodone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Hydrocodone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Hydrocodone can be decreased when it is combined with Rifapentine.Approved
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
RitobegronRitobegron may increase the analgesic activities of Hydrocodone.Investigational
RitonavirThe serum concentration of Hydrocodone can be decreased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Hydrocodone can be decreased when combined with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Rolofylline.Investigational
RopiniroleHydrocodone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
RotigotineHydrocodone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Hydrocodone.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Hydrocodone.Withdrawn
SaquinavirThe serum concentration of Hydrocodone can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Hydrocodone.Approved, Vet Approved
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Hydrocodone.Approved, Investigational, Vet Approved
SepranoloneUc1010 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
SertralineThe metabolism of Hydrocodone can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
SildenafilThe serum concentration of Hydrocodone can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Hydrocodone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Hydrocodone can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Hydrocodone.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Hydrocodone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolStiripentol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Hydrocodone.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
SulfisoxazoleThe serum concentration of Hydrocodone can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
SuvorexantSuvorexant may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TelaprevirThe serum concentration of Hydrocodone can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Hydrocodone can be increased when it is combined with Telithromycin.Approved
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TerbinafineThe serum concentration of Hydrocodone can be decreased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
ThalidomideHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Theobromine.Approved
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Hydrocodone.Withdrawn
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TicagrelorThe serum concentration of Hydrocodone can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Hydrocodone can be increased when it is combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ticrynafen.Withdrawn
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Hydrocodone.Approved
TipranavirThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Tipranavir resulting in a loss in efficacy.Approved, Investigational
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TocilizumabThe serum concentration of Hydrocodone can be decreased when it is combined with Tocilizumab.Approved
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Hydrocodone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Hydrocodone.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tolvaptan.Approved
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TorasemideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Torasemide.Approved
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TrametinibThe serum concentration of Hydrocodone can be decreased when it is combined with Trametinib.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Hydrocodone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydrocodone.Approved
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Triamterene.Approved
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hydrocodone.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Hydrocodone.Approved
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Hydrocodone.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Hydrocodone.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Hydrocodone.Approved
UlaritideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Hydrocodone.Approved
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hydrocodone.Approved
VemurafenibThe serum concentration of Hydrocodone can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Hydrocodone can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Hydrocodone can be increased when it is combined with Verapamil.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
VoriconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ZimelidineHydrocodone may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.
  • To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).
References
Synthesis Reference

Anne M. Hailes, Christopher E. French, Neil C. Bruce, "Morphinone reductase for the preparation of hydromorphone and hydrocodone." U.S. Patent US5571685, issued November, 1990.

US5571685
General ReferencesNot Available
External Links
ATC CodesR05DA03 — Hydrocodone
AHFS Codes
  • 48:08.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (48.8 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentFracture, Ankle1
0WithdrawnTreatmentPain / Painful musculoskeletal conditions1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHepatic Impairment1
1CompletedNot AvailableImpaired Renal Function1
1CompletedNot AvailablePain1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedTreatmentDrug Abuse1
1Not Yet RecruitingTreatmentHealthy Volunteers1
1RecruitingTreatmentHead and Neck Carcinoma / Oral Mucositis1
1WithdrawnTreatmentOpioid-Related Disorders / Pain, Acute / Postoperative pain2
2CompletedNot AvailableDegenerative Joint Disease1
2CompletedNot AvailablePostoperative pain1
2CompletedTreatmentChronic Low Back Pain (CLBP)1
2CompletedTreatmentOpioid-Related Disorders1
2CompletedTreatmentPain6
2Not Yet RecruitingTreatmentPain1
2Not Yet RecruitingTreatmentPainful musculoskeletal conditions1
2RecruitingTreatmentCorneal Abrasions / Eye Trauma1
3CompletedPreventionNausea / Pain / Vomiting1
3CompletedSupportive CareAnalgesia After ED Discharge for Extremity Injuries1
3CompletedTreatmentBack Pain Lower Back Chronic1
3CompletedTreatmentChronic Low Back Pain (CLBP)4
3CompletedTreatmentChronic Nonmalignant and Nonneuropathic Pain1
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentModerate to Severe Chronic, Non-malignant Pain1
3CompletedTreatmentNausea / Pain / Vomiting1
3CompletedTreatmentPain3
3CompletedTreatmentPain, Chronic1
3CompletedTreatmentSynovitis of osteoarthritis1
3RecruitingSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3TerminatedNot AvailablePost Operative Pain1
4CompletedNot AvailablePain, Chronic1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Vascular / Dementias / Pain1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentPain1
4CompletedTreatmentToothache1
4Enrolling by InvitationTreatmentCarpal Tunnel / Cystic tumour of the ganglia / De Quervain's Disease / Trigger Finger1
4Not Yet RecruitingTreatmentBody Weight Changes / Postoperative Hemorrhages / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
4Not Yet RecruitingTreatmentPain1
4Not Yet RecruitingTreatmentPain Management1
4RecruitingSupportive CareCarpal Tunnel1
4RecruitingSupportive CareColon Diverticulosis / Colonic Neoplasms / Constipation Drug Induced / Diverticulitis, Colonic / Ileus / Ileus paralytic / Ileus; Mechanical / Malignant Neoplasm of Colon / Occasional Constipation / Postoperative pain / Rectum Cancer / Rectum Neoplasm1
4RecruitingTreatmentPain1
4SuspendedTreatmentRotator Cuff Syndrome1
4TerminatedTreatmentAdverse Reaction to Drug / Obstructive Sleep Apnea (OSA) / Recurrent Tonsillitis / Sleep Disordered Breathing (SDB)1
4TerminatedTreatmentCarpal Tunnel Syndrome (CTS)1
Not AvailableCompletedTreatmentChildren / Laceration / Pain / Procedures1
Not AvailableCompletedTreatmentContraception / Inhalation of Nitrous Oxide1
Not AvailableCompletedTreatmentDrug Interactions1
Not AvailableCompletedTreatmentSkin Laxity1
Not AvailableNot Yet RecruitingTreatmentPain1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingTreatmentCancer, Breast / Postoperative pain1
Not AvailableUnknown StatusNot AvailableAnalgesic Response1
Not AvailableWithdrawnSupportive CareToothache1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
LiquidOral
SyrupOral1 mg
TabletOral5 mg
SolutionOral
TabletOral
Suspension, extended releaseOral
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral120 mg/1
Tablet, extended releaseOral20 mg/1
Tablet, extended releaseOral30 mg/1
Tablet, extended releaseOral40 mg/1
Tablet, extended releaseOral60 mg/1
Tablet, extended releaseOral80 mg/1
SyrupOral
Kit
Capsule, extended releaseOral
SuspensionOral
Tablet, extended releaseOral
Tablet, coatedOral
Tablet, film coatedOral
Capsule, extended releaseOral10 mg/1
Capsule, extended releaseOral15 mg/1
Capsule, extended releaseOral20 mg/1
Capsule, extended releaseOral30 mg/1
Capsule, extended releaseOral40 mg/1
Capsule, extended releaseOral50 mg/1
Prices
Unit descriptionCostUnit
Hydrocodone-Acetaminophen 7.5-500 mg/15ml Solution 473ml Bottle60.97USD bottle
Hydrocodone-Ibuprofen 7.5-200 mg tablet1.13USD tablet
Hydrocodone-Acetaminophen 10-750 mg tablet1.1USD tablet
Hydrocodone-Acetaminophen 7.5-325 mg tablet0.63USD tablet
Hydrocodone-Acetaminophen 10-325 mg tablet0.57USD tablet
Hydrocodone-Acetaminophen 5-325 mg tablet0.57USD tablet
Hydrocodone-Acetaminophen 10-660 mg tablet0.53USD tablet
Hydrocodone-Acetaminophen 10-500 mg tablet0.5USD tablet
Hydrocodone-Acetaminophen 10-650 mg tablet0.47USD tablet
Hydrocodone-Acetaminophen 7.5-500 mg tablet0.47USD tablet
Hydrocodone-Acetaminophen 2.5-500 mg tablet0.43USD tablet
Hydrocodone-Acetaminophen 7.5-750 mg tablet0.43USD tablet
Hydrocodone-Acetaminophen 5-500 mg tablet0.4USD tablet
Hydrocodone-Acetaminophen 7.5-650 mg tablet0.16USD tablet
Hydrocodone-Homatropine 5-1.5 mg/5ml Syrup0.15USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US9265760 No2013-07-232033-07-23Us
US6599531 No1997-06-102017-06-10Us
US6348216 No1997-06-102017-06-10Us
US6228398 No1999-11-012019-11-01Us
US8309060 No2003-11-202023-11-20Us
US6488963 No1997-06-242017-06-24Us
US9060940 No2001-10-302021-10-30Us
US8808740 No2011-12-212031-12-21Us
US6733783 No2001-10-302021-10-30Us
US9095614 No2007-08-242027-08-24Us
US9095615 No2007-08-242027-08-24Us
US8361499 No2001-10-302021-10-30Us
US9084816 No2007-08-242027-08-24Us
US9205056 No2001-10-302021-10-30Us
US8647667 No2001-10-302021-10-30Us
US9198863 No2001-10-302021-10-30Us
US9289391 No2001-10-302021-10-30Us
US9056052 No2001-10-302021-10-30Us
US8529948 No2002-08-062022-08-06Us
US8551520 No2001-10-302021-10-30Us
US9023401 No2001-10-302021-10-30Us
US9326982 No2013-07-252033-07-25Us
US6902742 No1999-11-012019-11-01Us
US9132096 No2014-09-122034-09-12Us
US9492389 No2007-08-242027-08-24Us
US9492391 No2007-08-242027-08-24Us
US9549907 No2015-11-132035-11-13Us
US9572804 No2000-10-302020-10-30Us
US9669023 No2000-10-302020-10-30Us
US9486412 No2007-08-242027-08-24Us
US9669024 No2000-10-302020-10-30Us
US9572779 No2011-12-212031-12-21Us
US9486413 No2007-08-242027-08-24Us
US9517236 No2000-10-302020-10-30Us
US9492390 No2007-08-242027-08-24Us
US9675611 No2000-10-302020-10-30Us
US9682077 No2000-10-302020-10-30Us
US9545380 No2007-08-242027-08-24Us
US9333201 No2013-07-252033-07-25Us
US9610286 No2013-07-252033-07-25Us
US9452163 No2014-09-122034-09-12Us
US9486451 No2014-09-122034-09-12Us
US9339499 No2013-07-252033-07-25Us
US9421200 No2013-07-252033-07-25Us
US9433619 No2013-07-252033-07-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)198 °CPhysProp
water solubilityInsolubleNot Available
logP1.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.797 mg/mLALOGPS
logP2.13ALOGPS
logP1.96ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)18ChemAxon
pKa (Strongest Basic)8.61ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.77 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.74 m3·mol-1ChemAxon
Polarizability32.05 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9984
Caco-2 permeable+0.8621
P-glycoprotein substrateSubstrate0.8253
P-glycoprotein inhibitor IInhibitor0.6425
P-glycoprotein inhibitor IINon-inhibitor0.8664
Renal organic cation transporterInhibitor0.6604
CYP450 2C9 substrateNon-substrate0.8546
CYP450 2D6 substrateSubstrate0.8997
CYP450 3A4 substrateSubstrate0.8168
CYP450 1A2 substrateNon-inhibitor0.8207
CYP450 2C9 inhibitorNon-inhibitor0.9412
CYP450 2D6 inhibitorInhibitor0.6629
CYP450 2C19 inhibitorNon-inhibitor0.8402
CYP450 3A4 inhibitorNon-inhibitor0.7625
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8675
Ames testNon AMES toxic0.7735
CarcinogenicityNon-carcinogens0.9419
BiodegradationNot ready biodegradable0.984
Rat acute toxicity3.0914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9024
hERG inhibition (predictor II)Non-inhibitor0.8165
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Download (10.3 KB)
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0udi-0009000000-f21858df54194757e2d9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0udi-0009000000-9b129b5d29df52345272View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0udi-0649000000-82623b23b75f0a0b232dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0002-0920000000-b67ff5a32d0ddd40c4c7View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-006t-0900000000-0277ba7435a4081ab333View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0g6v-0900000000-b335c52fad1274cd28cbView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0005-6970000000-3ba3e105098639cd6091View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative ParentsPhenanthrenes and derivatives / Isoquinolones and derivatives / Tetralins / Coumarans / Anisoles / Aralkylamines / Alkyl aryl ethers / Piperidines / Trialkylamines / Ketones
SubstituentsMorphinan / Phenanthrene / Isoquinolone / Tetralin / Coumaran / Anisole / Alkyl aryl ether / Aralkylamine / Piperidine / Benzenoid
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorsorganic heteropentacyclic compound (CHEBI:5779 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Uniprot Name:
Mu-type opioid receptor
Molecular Weight:
44778.855 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kotzer CJ, Hay DW, Dondio G, Giardina G, Petrillo P, Underwood DC: The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther. 2000 Feb;292(2):803-9. [PubMed:10640321 ]
  3. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16. [PubMed:16291875 ]
  4. Hennies HH, Friderichs E, Schneider J: Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988 Jul;38(7):877-80. [PubMed:2849950 ]
  5. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4. [PubMed:14600248 ]
  6. Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL: Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl). 2010 Oct;212(2):193-203. doi: 10.1007/s00213-010-1942-4. Epub 2010 Jul 28. [PubMed:20665209 ]
  7. Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr: The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008 Dec 1;98(3):191-202. doi: 10.1016/j.drugalcdep.2008.05.007. Epub 2008 Jul 7. [PubMed:18606504 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Uniprot Name:
Delta-type opioid receptor
Molecular Weight:
40368.235 Da
References
  1. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16. [PubMed:16291875 ]
  2. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4. [PubMed:14600248 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Uniprot Name:
Cytochrome P450 2D6
Molecular Weight:
55768.94 Da
References
  1. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97. [PubMed:14998425 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97. [PubMed:14998425 ]
Drug created on June 13, 2005 07:24 / Updated on August 08, 2017 11:06